J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Tumor Markers in Ovarian Malignancies.
TL;DR: How CA125 in combination with other tests can be used in the differential diagnosis of pelvic masses and as part of the investigations for cancer screening is discussed.
Journal Article
Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer.
Jonathan A. Ledermann,Tim Maughan,Roger D James,D. Kerr,Colin S. McArdle,Matthew T. Seymour,C Johnston,Richard Stephens +7 more
Journal ArticleDOI
DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma
Anjana A. Kulkarni,Marco Loddo,Elisabetta Leo,Mohammed Ahmed Rashid,Kathryn Leigh Eward,Thomas R. Fanshawe,Jessica Butcher,Alison Frost,Jonathan A. Ledermann,Gareth H. Williams,Kai Stoeber +10 more
TL;DR: The data show that Ki67, Mcm2, geminin and Aurora A and B can be used as an adjunct to conventional prognostic indicators and as an aid to develop a tumor progression model for EOC.
Journal ArticleDOI
ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis
Andrew R Clamp,Iain A. McNeish,Andrew Dean,D Gallardo,J Weon-Kim,Dearbhaile M. O'Donnell,Jane Hook,C. Coyle,Sarah P. Blagden,James D. Brenton,Raj Naik,Timothy J. Perren,Sudha Sundar,Adrian Cook,Elizabeth C. James,Ann Marie Swart,S. P. Stenning,Richard Kaplan,Jonathan A. Ledermann +18 more
Journal ArticleDOI
Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM).
T.J.M. Ruers,C.J.A. Punt,F. van Coevorden,I. H. M. Borel Rinkes,Jonathan A. Ledermann,Graeme J. Poston,Wolf O. Bechstein,M.A. Lentz,Murielle Mauer,Bernard Nordlinger +9 more
TL;DR: This randomised phase II study evaluated the benefits of adding RFA to systemic CT in patients with ≤ 9 unresectable CRC LM and no extrahepatic disease to exclude a 30-months overall survival rate ≤ 38% with RFA + CT.